Press Releases

Date	Title
7/28/11	AVI BioPharma Announces Second Quarter 2011 Financial Results and Corporate Update Conference Call
7/25/11	The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant and Dose-Dependent Expression of Dystrophin in Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen
6/21/11	AVI BioPharma Expands Clinical Pipeline With Initiation of Phase 1 Study of Influenza Therapeutic Candidate
6/16/11	AVI BioPharma and Naval Medical Research Center Successfully Complete Simultaneous Rapid-Response Exercises Against Bacterial and Viral Threats in 18 Days
6/9/11	AVI BioPharma Provides Update on Initiation of Eteplirsen Phase 2 Clinical Trial
6/6/11	AVI BioPharma Names Ed Kaye, M.D., Chief Medical Officer
5/19/11	AVI BioPharma to Present Company Overview at the ThinkEquity 2nd Annual Healthcare Conference
5/17/11	AVI BioPharma Issued Broad Composition of Matter Patent for PMOplus(TM) Chemistry Platform
5/6/11	Data From AVI BioPharma's RNA-Based Hemorrhagic Fever and Infectious Disease Programs to Be Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases
5/5/11	AVI BioPharma Announces First Quarter 2011 Financial Results

IR Menu